Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects

NCT07181265 | Not Yet Recruiting Phase 1

• 1 other identifier: JMKX003142-103
• Study Type: interventional
• Target: 48
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a open-label, non-randomized, multiple oral dosings, three-period, drug-drug interaction study of JMKX003142 tablet, Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Chinese healthy adult subjects

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Outcome Measures

Primary Outcomes (2)

• Cmax，ss

  up to 7 days

• AUC0-tau

  up tp 7 days

Secondary Outcomes (2)

• Tmax

  up to 7 days

• AUC0-t

  up to 7 days

Study Arms (2)

Drug-Drug interaction study of JMKX003142 and Amiodarone

EXPERIMENTAL

24 Subjects first administered with JMKX003142 tablets 4mg from day 1 to day 7 after breakfast. from day 12 to day 18 the subjects were adminstered with Amiodarone Hydrochloride Tablets 400 mg. from day 22 to day 28 these subjects were co-adminstered with JMKX003142 tablets 4mg and Amiodarone Hydrochloride Tablets 400 mg.

Drug: Amiodarone Hydrochloride Tablets

Drug-Drug interaction study of JMKX003142 with Febuxostat

EXPERIMENTAL

24 Subjects first administered with JMKX003142 tablets 4mg from day 1 to day 7 after breakfast. from day 12 to day 18 the subjects were adminstered with Febuxostat Tablets 40 mg. from day 21 to day 27 these subjects were co-adminstered with JMKX003142 tablets 4mg and Febuxostat Tablets 40 mg.

Drug: Febuxostat Tablets

Interventions

Amiodarone Hydrochloride Tablets DRUG

Cohort 1: The intervention is for study of drug drug interaction of JMKX003142 when administered with Amiodarone

Drug-Drug interaction study of JMKX003142 and Amiodarone

Febuxostat Tablets DRUG

Cohort 2: The intervention is for study of drug drug interaction of JMKX003142 when administered with Febuxostat Tablets

Drug-Drug interaction study of JMKX003142 with Febuxostat

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study.
• Healthy adult males and/or females, 18 to 45 years of age (inclusive) at the date of signed consent form. Body mass index (BMI) greater than or equal to 18 and less than 32 (kg/m2) and a minimum body weight of 45 kg.
• The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead electrocardiogram, all of which were determined by the investigator to be normal or not clinically significant.
• Women of child-bearing potential and sexually active males willing to use highly effective methods of contraception from screening until 3 months after last dose of study drug. In addition, participants must not donate sperm/egg for the time period specified above.

You may not qualify if:

• Subjects having hypersensitivity to study drug or have a history of allergies to multiple drugs, foods, or other substances
• History or presence of significant circulatory system, respiratory system, digestive system, blood system, urinary and reproductive system, endocrine and metabolic system, nervous system, mental system, muscular and skeletal system, skin system, lymphatic system, immune system, Otolaryngology or other related systems disease or disorder. as well as systemic or local acute or chronic infections.
• Subjects with dysphagia, gastrointestinal diseases, or any conditions that may affect drug absorption; such as a history of hepatobiliary and pancreatic diseases, gastrointestinal diseases, gastrointestinal surgery (except appendectomy), or a history of chronic pancreatitis, idiopathic acute pancreatitis, or habitual diarrhea.
• Vital signs during the screening period meet any of the following conditions: systolic blood pressure \>140 mmHg or \<90 mmHg; diastolic blood pressure \>90 mmHg or \<50 mmHg (Cohort 1: diastolic blood pressure \>90 mmHg or \<60 mmHg); pulse \>100 beats/min or \<50 beats/min (Cohort 1: pulse \>100 beats/min or \<60 beats/min); ear temperature \>37.5°C or \<35°C.
• History of QTc interval prolongation or abnormal ECG results during screening, QTcF ≥ 450 ms for males or ≥ 470 ms for females, or QRS interval \> 120 ms.

Sponsors & Collaborators

• Jemincare: lead

MeSH Terms

Conditions

Polycystic Kidney, Autosomal Dominant

Interventions

Amiodarone; Febuxostat

Condition Hierarchy (Ancestors)

Polycystic Kidney Diseases; Kidney Diseases, Cystic; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Abnormalities, Multiple; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Ciliopathies; Genetic Diseases, Inborn

Intervention Hierarchy (Ancestors)

Benzofurans; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Thiazoles; Sulfur Compounds; Organic Chemicals; Azoles; Heterocyclic Compounds, 1-Ring

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 12, 2025
• First Posted: September 18, 2025
• Study Start: October 30, 2025
• Primary Completion: April 30, 2026
• Study Completion (Estimated): June 30, 2026
• Last Updated: September 18, 2025

Record last verified: 2025-09